<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(23)</volume><submitter>Zou P</submitter><pubmed_abstract>Hyperplasia (i.e., increased adipogenesis) contributes to excess adiposity, the hallmark of obesity that can trigger metabolic complications. As FoxO1 has been implicated in adipogenic regulation, we investigated the kinetics of FoxO1 activation during adipocyte differentiation, and tested the effects of FoxO1 antagonist (AS1842856) on adipogenesis. We found for the first time that the kinetics of FoxO1 activation follows a series of sigmoid curves, and reveals the phases relevant to clonal expansion, cell cycle arrest, and the regulation of PPARγ, adiponectin, and mitochondrial proteins (complexes I and III). In addition, multiple activation-inactivation transitions exist in the stage of terminal differentiation. Importantly, persistent inhibition of FoxO1 with AS1842856 almost completely</pubmed_abstract><journal>Cell cycle (Georgetown, Tex.)</journal><pagination>3759-67</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4613185</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeting FoxO1 with AS1842856 suppresses adipogenesis.</pubmed_title><pmcid>PMC4613185</pmcid><pubmed_authors>Liu L</pubmed_authors><pubmed_authors>Emery A</pubmed_authors><pubmed_authors>Zheng L</pubmed_authors><pubmed_authors>Stoneman RE</pubmed_authors><pubmed_authors>Zou P</pubmed_authors><pubmed_authors>Gilbert ER</pubmed_authors><pubmed_authors>Cho A</pubmed_authors><pubmed_authors>Cheng Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting FoxO1 with AS1842856 suppresses adipogenesis.</name><description>Hyperplasia (i.e., increased adipogenesis) contributes to excess adiposity, the hallmark of obesity that can trigger metabolic complications. As FoxO1 has been implicated in adipogenic regulation, we investigated the kinetics of FoxO1 activation during adipocyte differentiation, and tested the effects of FoxO1 antagonist (AS1842856) on adipogenesis. We found for the first time that the kinetics of FoxO1 activation follows a series of sigmoid curves, and reveals the phases relevant to clonal expansion, cell cycle arrest, and the regulation of PPARγ, adiponectin, and mitochondrial proteins (complexes I and III). In addition, multiple activation-inactivation transitions exist in the stage of terminal differentiation. Importantly, persistent inhibition of FoxO1 with AS1842856 almost completely</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014</publication><modification>2025-04-22T11:39:25.544Z</modification><creation>2019-03-27T02:00:25Z</creation></dates><accession>S-EPMC4613185</accession><cross_references><pubmed>25483084</pubmed><doi>10.4161/15384101.2014.965977</doi></cross_references></HashMap>